(MedPage Today) — Eteplirsen review pushed to 2016, while drisapersen reviewed as scheduled
Category: News
Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman, will participate in a fireside chat presentation at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015 at 9:30 a.m. ET at The New York Palace Hotel in New York C
Expert Opinion in Managing Aqueous Deficient Dry Eye Disease
A survey of dry eye experts provides insight into the most commonly used treatment strategies for aqueous deficient dry eye disease. BMC Ophthalmology
Visual stress could be a symptom of Chronic Fatigue Syndrome, research suggests
University of Leicester research team discovers vision-related abnormalities that could help in diagnosis of illnessPeople suffering from Chronic Fatigue Syndrome (CFS) could experience…
Amblyopia, not strabismus, identified as key contributor to slow reading in school-age children
Children with amblyopia, commonly known as “lazy eye,” may have impaired ocular motor function.
Ocular Therapeutix™ Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today enrollment of the first patients in a second Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone), 0.4mg Intracanalicular Depot for the treatment of allergic conjunctivitis. DEXTENZA is a product candidate administer
Inotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
Second Sight to Present at Piper Jaffray 27th Annual Healthcare Conference
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced today that Will McGuire, President and Chief Executive Officer, will present at the Piper Jaffray 27th Annual Healthcare Conference as follows: Date: Wednesday, December 2, 2015 Time: 3:00 p.m. EST Location: Lotte New York Palace
Healthcare Mergers: Good, Bad, or Both?
(MedPage Today) — Experts explore its benefits and consequences
CMS Seeks Network Adequacy for ACA Exchange Plans
(MedPage Today) — If state doesn’t select applicable metrics, CMS will
Value-Based Pricing Will Help With High Rx Costs
(MedPage Today) — More data needed to put it into practice, experts say
Study identifies amblyopia as key factor for poor reading in school-age children
Children with amblyopia, commonly known as “lazy eye,” may have impaired ocular motor function. This can result in difficulties in activities for which sequential eye movements are important, such as reading.
New Strategies but Modest Benefit in Uveal Melanoma
New therapies being tried in uveual melanoma include combination everolimus, pasireotide long-acting release, and the MEK inhibitor trametinib. Medscape Medical News
2015 Brings Bumper Crop of New Rx Meds
(MedPage Today) — Could be record year for new drug approvals
Direct funduscopy exams performed infrequently, finds Loyola study
For more than 150 years, physicians have examined patients’ eyes with a lighted, hand-held instrument called an ophthalmoscope.
D.C. Week: Mostly Smooth Sailing for FDA Nominee at Senate Hearing
(MedPage Today) — The FDA releases a report on potentially dangerous laboratory developed tests
What We Heard This Week
(MedPage Today) — Quotable quotes from MedPage Today’s news coverage
Neural Deficit Progresses After Collagen Crosslinking for Keratoconus
Collagen crosslinking (CXL) treatment appears to halt the progression of keratoconus in young patients, but nerve disorientation persists, according to European investigators. Reuters Health Information
Baerveldt Has Edge on Ahmed in Glaucoma at 5 Years
For patients with refractory glaucoma, intraocular pressure was lower with the Baerveldt implant than with the Ahmed valve, and fewer medications were required, but the risk for hypotony was greater. Medscape Medical News
New Dry Eye Gel Improves Some, but Not All, Symptoms
A carbomer-based lipid-containing artificial tear formulation improved patients’ ocular surface staining grades and ocular irritation symptom scores and decreased symptoms in patients with dry eye. Medscape Medical News